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Therapeutic strategies targeting the epidermal growth factor
receptor (EGFR) are being evaluated in a number of ongoing
clinical studies in non-small cell lung cancer (NSCLC). EGFR
tyrosine kinase inhibitors (TKIs) are currently used worldwide
to treat advanced refractory NSCLC, whereas the efficacy of
anti-EGFR monoclonal antibodies remains to be established.
Using molecular profiling to select patients to receive earlier
EGFR targeted therapy as first-line treatment or in the adjuvant
setting is an area of active research. Based on preclinical data,
combining EGFR TKIs with other treatment modalities has
promise, and clinical validation is underway. A new generation
of irreversibly bound EGFR TKIs is being developed, and
insights into the molecular biology of NSCLC should help to
better define the patients who are most likely to benefit from
these compounds. We summarize updates on EGFR targeted
therapies that were presented during the sixth annual Targeted
Therapies for the Treatment of Lung Cancer Conference in Los
Angeles, CA; January 27–28, 2006.
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MOLECULAR STRATEGIES TO SELECT
PATIENTS FOR EPIDERMAL GROWTH FACTOR
RECEPTOR TYROSINE KINASE INHIBITOR
THERAPY
There are several clinical features of patients with
non-small cell lung cancer (NSCLC) that are established
predictors of response to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) therapy, including a
never-smoking history, Asian race, female gender, and ade-
nocarcinoma histology. However, data from the BR.21 study,
a phase III randomized, placebo-controlled trial of salvage
erlotinib, indicates that erlotinib yields a survival benefit even
among patients without these features.1 Because clinical char-
acteristics are insufficient to guide decision-making, a large
international research effort is ongoing to identify biomarkers
of response and survival benefit in patients treated with
EGFR TKIs. EGFR protein expression, EGFR gene copy
number, and EGFR tyrosine kinase mutations are the leading
biomarkers. Dr. Fred R. Hirsch from the University of Col-
orado Cancer Center presented new data about the utility of
these biomarkers from the patients with available tissue
participating in the ISEL study, a phase III randomized,
placebo-controlled trial of salvage gefitinib.2 Patients with
high EGFR polysomy or true gene amplification as deter-
mined by fluorescence in situ hybridization (FISH), together
termed FISH, trended toward prolonged survival when
treated with gefitinib compared with placebo (hazard ratio
[HR] 0.61, 95% confidence interval [CI] 0.36-1.04). This
suggests that EGFR FISH is a useful method to predict
survival with TKI therapy, as was seen in the molecular
subgroup analysis of the BR.21 erlotinib trial and in other
retrospectively analyzed cohorts of gefitinib-treated pa-
tients.3–5 Furthermore, Dr. Hirsh found that, in the ISEL trial,
EGFR protein expression measured by immunohistochemis-
try staining (IHC) could identify a subset of patients that
trended toward a survival benefit from gefitinib therapy (HR
0.77, 95% CI 0.56-1.08). However, the benefit in IHC
patients was not as striking as that in FISH  patients.
Dr. Frances Shepherd from the University of Toronto
presented new data on the molecular analyses of the BR.21
trial. Additional patient tumor samples have been added to
her analysis since the original publication by Tsao and col-
leagues. Furthermore, it included only the classically de-
scribed mutations, exon 19 deletions and exon 21 leucine to
arginine substitution at codon 858 (L858R), in response to
criticisms that Tsao et al.’s article included a high number of
novel mutations.6 Dr. Shepherd reported that the proportion
of tumors harboring a classic EGFR mutation was 11.9% and
that EGFR mutation-positive patients did not achieve a sur-
vival benefit from erlotinib therapy compared with placebo
(HR 0.64, 95% CI 0.24-1.75). Furthermore, patients with
increased gene copy number (FISH) had a higher response
rate to erlotinib therapy compared with FISH- patients (20%
versus 2.4%; P  0.03) and a survival benefit with erlotinib
treatment compared with placebo (HR 0.44, 95% CI 0.2-
0.82). Dr. Shepherd also emphasized the value of testing
EGFR protein expression by IHC. She presented a combined
analysis with the molecular data from the ISEL, BR.21, and
IDEAL (two phase II studies with gefitinib) trials. IHC
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patients from these three cohorts had a higher response rate to
TKI therapy compared with IHC- patients (10.9% versus
3.0%; P  0.003).
Dr. Bruce Johnson from the Dana-Farber Cancer Insti-
tute discussed clinical situations in which EGFR mutation
testing might be clinically relevant and emphasized the im-
portance of prospectively identifying patients that may dra-
matically benefit from TKI therapy and of molecular charac-
terization of acquired resistance to EGFR TKIs. EGFR
mutations have been retrospectively associated with in-
creased response rate and survival benefit from TKI therapy,
but these findings need to be validated in clinical trials
enrolling a molecularly selected population.7–12 In addition,
prospective studies are needed to confirm reports that suggest
survival may be increased for exon 19 deletion mutation
patients treated with EGFR TKIs compared with L858R point
mutation patients.13–15 Finally, Dr. Johnson pointed out that
new technologies are being developed that can rapidly detect
mutations with unprecedented sensitivity.16
EGFR TYROSINE KINASE INHIBITORS IN
COMBINATION WITH OTHER AGENTS
There is a strong precedent for targeted therapeutics to
demonstrate enhanced activity when used in combination
with chemotherapy, as seen with chemotherapy and trastu-
zumab in breast cancer, cetuximab in colon cancer, bevaci-
zumab in colon cancer, and bevacizumab in NSCLC.17–20
However, four large randomized trials of first-line combina-
tion chemotherapy plus an EGFR TKI for NSCLC including
more than 4000 patients in total each failed to show an
advantage to this strategy.21–24 Dr. David R. Gandara from
the University of California at Davis discussed potential
explanations for the failure of first-line EGFR TKIs with
chemotherapy. He posited that lack of proper patient selec-
tion, via the molecular strategies discussed above, could
account for the negative results. If an insufficient number of
patients with markers of TKI-responsive disease were re-
cruited for the studies and/or were randomized to the TKI
arms, a true treatment benefit may have been missed. Retro-
spective analyses to validate this theory have been limited or
inconclusive because only a few patients enrolled in clinical
trials have available archived tissue for molecular analy-
sis.25,26 There is indirect evidence that a randomized trial with
more stringent patient selection could show a survival benefit.
In a prespecified subset analysis of the TRIBUTE trial of
carboplatin and paclitaxel combined with erlotinib or pla-
cebo, never-smokers (a patient characteristic associated with
EGFR mutations) achieved a survival benefit with erlotinib
treatment compared with placebo.23
A second explanation for the lack of benefit from
combination therapy is that EGFR TKIs could have a nega-
tive interaction or antagonism when given with chemother-
apy, at least in a subset of patients. Dr. Gandara hypothesized
that EGFR TKIs induce apoptosis only in EGFR-mutated
NSCLC and induce cell cycle arrest in wild-type tumors.
Because chemotherapy is active in the S and M phases of the
cell cycle, wild-type cells in G1 arrest because of constant
TKI exposure may be less responsive to chemotherapy. There
is preclinical evidence to support this theory. EGFR TKIs
induce apoptosis in NSCLC cell lines known to harbor a
mutation but not in wild-type cell lines.27 Furthermore,
NSCLC cell lines and xenograft models exposed to concur-
rent continuous EGFR TKI and chemotherapy undergo less
cell kill compared with sequential or intermittent expo-
sure.28,29 Because most patients in these trials are presumed to
have wild-type EGFR, this mechanism could have had a
major impact on the trial results. There are ongoing prospec-
tive trials examining sequential and pharmacodynamically
separated chemotherapy and EGFR TKIs to further under-
stand the interaction.
Concurrent use of EGFR TKIs with the anti-inflamma-
tory cyclooxygenase-2 (COX-2) inhibitors was discussed by
Dr. Karen Reckamp from the University of California at Los
Angeles. COX-2 overexpression is seen in many malignan-
cies, including NSCLC, and leads to increased prostaglandin
E2 (PGE2) levels, which in turn promote many features of
tumorigenesis, such as angiogenesis, metastasis, and resis-
tance to apoptosis.30 PGE2 can stimulate cancer cell growth
via Erk-mediated signaling, which is independent from the
EGFR pathway, and suggests that the COX-2/PGE2 pathway
may be important in clinical EGFR TKI resistance.31 In
addition, PGE2 inhibits E-cadherin expression, which has
been shown to diminish sensitivity to EGFR TKIs.32 Dr.
Reckamp presented results from a phase I trial using the
COX-2 inhibitor celecoxib in combination with erlotinib in
patients with NSCLC. The combination was well tolerated,
and early analyses show that some patients with wild-type
EGFR tumors have a partial response to celecoxib plus
erlotinib. Phase II studies of this combination are ongoing.
ANTI-EGFR MONOCLONAL ANTIBODIES
The anti-EGFR monoclonal antibodies most advanced
in clinical development in NSCLC include cetuximab
(C225), matuzumab (EMD72000), and panitumumab (ABX-
EGF). Dr. Edward Kim from the MD Anderson Cancer
Center reviewed the current state of clinical development of
cetuximab in NSCLC. Cetuximab is a chimeric IgG1 anti-
body approved for the treatment of colorectal and head and
neck cancers.18,33 It induces antibody-dependent cell cytotox-
icity. Cetuximab is currently being studied as part of first-line
combination therapy for NSCLC in a phase III registration
trial (EMR-046) in which patients are randomized to cisplatin
and vinorelbine with or without cetuximab. The design of this
study was based on a randomized phase II trial with the same
treatment arms as second-line therapy that demonstrated
promising response rates of 35% and 28% in patients treated
with chemotherapy plus cetuximab and chemotherapy alone,
respectively.34 In addition, cetuximab is being studied as
combination therapy in patients with chemo-refractory
NSCLC in a randomized trial (IMCL-0425) using pem-
etrexed or docetaxel, plus or minus cetuximab, based on a
27% response rate and a 7.5-month median survival seen with
docetaxel and cetuximab in a phase II study.35 Dr. Kim also
noted that, among several studies with cetuximab in advanced
cancer patients, the severity of rash has been correlated with
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survival, suggesting that biomarkers of the EGFR pathway
may help us to better select patients for treatment.
Dr. Joan Schiller from the University of Wisconsin
discussed other EGFR targeted antibodies in clinical devel-
opment. Matuzumab is a humanized IgG1 antibody, and
panitumumab is a human IgG2 antibody. They are both less
likely than cetuximab to induce human anti-murine antibody
(HAMA) responses, and therefore do not require hypersen-
sitivity premedication. Like cetuximab, matuzumab can in-
duce antibody-dependent cell cytotoxicity, whereas panitu-
mumab cannot. The different properties of these compounds
are difficult to assess clinically, especially in light of their
unproven clinical role in NSCLC management. Phase I data
among patients with treated with matuzumab in combination
with every 3-week paclitaxel at 175 mg/m2 were recently
reported.36 The combination was well tolerated, and four of
18 patients responded. Dr. Schiller presented a proposed
three-arm randomized phase II study evaluating pemetrexed,
and pemetrexed plus matuzumab at either 800 mg weekly or
1600 mg every 3 weeks as second-line treatment of advanced
disease. Panitumumab was studied as first-line therapy with
paclitaxel and carboplatin in as phase I/II trial.37 Although the
triplet seemed to be well tolerated, the phase II portion of the
trial including 166 patients randomized to chemotherapy plus
or minus panitumumab did not show a difference between the
arms in response rate, median time to progression, or sur-
vival. Molecular analyses of EGFR and K-ras mutations
performed in tumors from 88 participants of this study did not
show any association with response data.
There are several important questions to be answered
about anti-EGFR monoclonal antibodies in lung cancer, in-
cluding comparisons among the different antibodies in terms
of safety and efficacy, mechanisms underlying the association
of skin rash and treatment benefit, and outcomes of combi-
nations with cytotoxic therapy and other targeted agents.
Correlative studies of biomarkers that may predict treatment
benefit from these agents are also strongly needed.
IRREVERSIBLE EGFR INHIBITORS
Somatic activating EGFR mutations occur in only a
small population of patients with NSCLC, but they correlate
with dramatic responses to EGFR TKI therapy. The second-
ary acquired resistance mutation T790M has been described
in some patients with activating mutations that initially re-
sponded to EGFR TKI therapy but subsequently relapsed.38,39
The T790M mutation introduces a bulky residue at the TK
ATP-binding site, hindering TKIs from reaching the target.
However, it is not present in all TKI-resistant patients, and
there are several possible mechanisms of developing clinical
TKI resistance. Dr. Thomas Lynch from the Massachusetts
General Hospital Cancer Center discussed TKI resistance and
new strategies for resistant patients currently under clinical
investigation. In preclinical models, gefitinib-sensitive cell
lines can be used to generate TKI-resistant clones via con-
tinuous long-term exposure to the drug. These gefitinib-
resistant clones undergo significant cell kill by investigational
irreversibly bound EGFR TKIs such as HKI-272, EKB-569,
and HKI-357.40 It is thought that these TKIs are able to
overcome the steric hindrance from T790M mutations and
may also be able to combat other mechanisms of resistance,
such as altered receptor trafficking. Furthermore, it was not
possible to generate clones of cells that were resistant to
irreversible TKIs, even with prolonged high-dose exposure.
These findings are analogous to other cancers (chronic my-
elogenous leukemia and gastrointestinal stromal cell tumors)
that are dependent on mutated TK signaling and initially
demonstrate sensitivity to inhibitors but subsequently develop
resistance. In these cases, compounds that can overcome the
resistance mutations in vitro have been shown to be clinically
useful.41 Therefore, Dr. Lynch concluded that molecular
profiling of NSCLC tumors may be a useful strategy for
identifying cases that are potentially sensitive to irreversible
TKIs and may be clinically useful in both TKI-naı¨ve patients
and those previously treated with reversibly bound TKIs. To
validate this approach, there is an ongoing multicenter phase
II trial with the HKI-272 compound that stratifies patients
based on their EGFR mutational status and their prior TKI
exposure.
CONCLUSIONS AND FUTURE DIRECTIONS
EGFR TKIs have become a foundation in the treatment
of chemo-refractory NSCLC. The role of EGFR-targeted
kinase inhibitors and monoclonal antibodies in the manage-
ment of NSCLC continues to be refined, and new studies are
being launched in early-stage disease and in adjuvant set-
tings. Significant progress in translational research is leading
to the discovery of biomarkers to guide patient selection for
these treatments, the potential enhancement of activity
through combination with other treatment modalities, and the
clinical development of novel EGFR inhibitors. Continued
efforts in these areas will enable us to offer more effective
therapy options to our patients. A “bench to bedside” ap-
proach with rapid validation of biological hypotheses through
well-designed clinical trials is essential to achieve this goal.
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